Share
Greg Friberg
BioMarin Pharmaceutical Inc. has announced key leadership changes, appointing Greg Friberg, M.D., as Executive Vice President and Chief Research & Development Officer, and James Sabry, M.D., Ph.D., as Executive Vice President and Chief Business Officer.
Dr. Friberg, who joins BioMarin, brings nearly two decades of industry experience, having most recently served as Vice President of Global Medical Affairs, Rare Disease at Amgen. His extensive background in clinical development and lifecycle management, along with his leadership in advancing various medicines through development, makes him well-suited to oversee BioMarin’s R&D organization. This includes responsibility for discovery research, preclinical, translational and clinical programs, as well as global regulatory and medical affairs.
Dr. Sabry steps into his role as Chief Business Officer, following a 14-year tenure at Roche and Genentech, where he was Executive Vice President and Global Head of Roche Partnering. With over 1,200 transactions under his leadership, Dr. Sabry is recognized as a top business development executive in the biopharmaceutical industry. His expertise in identifying and managing innovations across all development stages will be key to BioMarin’s growth strategy.
Dr. Friberg succeeds Hank Fuchs, M.D., who is retiring after 15 years of leading BioMarin's R&D, while Dr. Sabry replaces Brinda Balakrishnan, M.D., Ph.D., who is stepping down as Chief Corporate Strategy and Business Development Officer.
These leadership appointments reflect BioMarin’s commitment to advancing its pipeline and continuing to deliver transformative medicines.
